Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Marc J. van de Vijver
Based on 4 articles published since 2009
(Why 4 articles?)

Between 2009 and 2019, M. van de Vijver wrote the following 4 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomy specimens. 2018

Soer, Eline / Brosens, Lodewijk / van de Vijver, Marc / Dijk, Frederike / van Velthuysen, Marie-Louise / Farina-Sarasqueta, Arantza / Morreau, Hans / Offerhaus, Johan / Koens, Lianne / Verheij, Joanne. ·Department of pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. e.c.soer@amc.uva.nl. · Department of pathology, University Medical Center, Utrecht, Netherlands. · Department of pathology, Radboud Medical Center, Nijmegen, Netherlands. · Department of pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. · Department of pathology, VU University Medical Center, Amsterdam, Netherlands. · Department of pathology, Erasmus Medical Center, Rotterdam, Netherlands. · Department of pathology, Leiden Medical Center, Leiden, Netherlands. ·Virchows Arch · Pubmed #29589102.

ABSTRACT: A pancreatoduodenectomy specimen is complex, and there is much debate on how it is best approached by the pathologist. In this review, we provide an overview of topics relevant for current clinical practice in terms of gross dissection, and macro- and microscopic assessment of the pancreatoduodenectomy specimen with a suspicion of suspected pancreatic cancer. Tumor origin, tumor size, degree of differentiation, lymph node status, and resection margin status are universally accepted as prognostic for survival. However, different guidelines diverge on important issues, such as the diagnostic criteria for evaluating the completeness of resection. The macroscopic assessment of the site of origin in periampullary tumors and cystic lesions is influenced by the grossing method. Bi-sectioning of the head of the pancreas may offer an advantage in this respect, as this method allows for optimal visualization of the periampullary area. However, a head-to-head comparison of the assessment of clinically relevant parameters, using axial slicing versus bi-sectioning, is not available yet and the gold standard to compare both techniques prospectively might be subject of debate. Further studies are required to validate the various dissection protocols used for pancreatoduodenectomy specimens and their specific value in the assessment of pathological parameters relevant for prognosis.

2 Review Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. 2017

Creemers, A / Krausz, S / Strijker, M / van der Wel, M J / Soer, E C / Reinten, R J / Besselink, M G / Wilmink, J W / van de Vijver, M J / van Noesel, C J M / Verheij, J / Meijer, S L / Dijk, F / Bijlsma, M F / van Oijen, M G H / van Laarhoven, H W M. ·Cancer Center Amsterdam, Center for Experimental and Molecular Medicine (CEMM)/Laboratory for Experimental Oncology and Radiobiology (LEXOR), AMC, The Netherlands; Cancer Center Amsterdam, Department of Medical Oncology, AMC, The Netherlands. Electronic address: a.creemers@amc.uva.nl. · Cancer Center Amsterdam, Department of Medical Oncology, AMC, The Netherlands. · Department of Surgery, AMC, The Netherlands. · Department of Pathology, AMC, The Netherlands. · Cancer Center Amsterdam, Center for Experimental and Molecular Medicine (CEMM)/Laboratory for Experimental Oncology and Radiobiology (LEXOR), AMC, The Netherlands. · Cancer Center Amsterdam, Center for Experimental and Molecular Medicine (CEMM)/Laboratory for Experimental Oncology and Radiobiology (LEXOR), AMC, The Netherlands; Cancer Center Amsterdam, Department of Medical Oncology, AMC, The Netherlands. ·Biochim Biophys Acta Rev Cancer · Pubmed #28801248.

ABSTRACT: BACKGROUND: The recent expanding technical possibilities to detect tumor derived mutations in blood, so-called circulating tumor DNA (ctDNA), has rapidly increased the interest in liquid biopsies. This review and meta-analysis explores the clinical value of ctDNA in malignancies of the upper gastro-intestinal tract. METHODS: PubMed, Cochrane and Embase databases were searched to identify studies reporting the diagnostic, prognostic or predictive value of ctDNA in patients with esophageal, gastric and pancreatic cancer, until January 2017. The diagnostic accuracy and, using random-effect pair-wise meta-analyses, the prognostic value of ctDNA was assessed. RESULTS: A total of 34 studies met the inclusion criteria. For esophageal and gastric cancer, amplification of oncogenes in blood, such as HER2 and MYC, can be relevant for diagnostic purposes, and to predict treatment response in certain patient subpopulations. Given the limited number of studies assessing the role of ctDNA in esophageal and gastric cancer, the meta-analysis estimated the diagnostic accuracy and predictive value of ctDNA in pancreatic cancer only (n=10). The pooled sensitivity and specificity of ctDNA as a diagnostic tool in pancreatic cancer were 28% and 95%, respectively. Patients with pancreatic cancer and detectable ctDNA demonstrated a worse overall survival compared to patients with undetectable ctDNA (HR 1.92, 95% confidence interval (CI) 1.15-3.22, p=0.01). CONCLUSION: The presence of ctDNA is significantly associated with a poor prognosis in patients with pancreatic cancer. The use of ctDNA in clinical practice is promising, although standardization of sequencing techniques and further development of high-sensitive detection methods is needed.

3 Review Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. 2016

van Rijssen, Lennart B / Rombouts, Steffi J E / Walma, Marieke S / Vogel, Jantien A / Tol, Johanna A / Molenaar, Isaac Q / van Eijck, Casper H J / Verheij, Joanne / van de Vijver, Marc J / Busch, Olivier R C / Besselink, Marc G H / Anonymous8590889. ·Department of Surgery, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. · Department of Surgery, University Medical Center, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands. · Department of Surgery, Erasmus Medical Center, Gravendijkwal 230, Rotterdam 3015 CE, The Netherlands. · Department of Pathology, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. · Department of Surgery, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. Electronic address: m.g.besselink@amc.uva.nl. ·Surg Pathol Clin · Pubmed #27926358.

ABSTRACT: Recent advances in pancreatic surgery have the potential to improve outcomes for patients with pancreatic cancer. We address 3 new, trending topics in pancreatic surgery that are of relevance to the pathologist. First, increasing awareness of the prognostic impact of intraoperatively detected extraregional and regional lymph node metastases and the international consensus definition on lymph node sampling and reporting. Second, neoadjuvant chemotherapy, which is capable of changing 10% to 20% of initially unresectable, to resectable disease. Third, in patients who remain unresectable following neoadjuvant chemotherapy, local ablative therapies may change indications for treatment and improve outcomes.

4 Article HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. 2017

Davies, Helen / Glodzik, Dominik / Morganella, Sandro / Yates, Lucy R / Staaf, Johan / Zou, Xueqing / Ramakrishna, Manasa / Martin, Sancha / Boyault, Sandrine / Sieuwerts, Anieta M / Simpson, Peter T / King, Tari A / Raine, Keiran / Eyfjord, Jorunn E / Kong, Gu / Borg, Åke / Birney, Ewan / Stunnenberg, Hendrik G / van de Vijver, Marc J / Børresen-Dale, Anne-Lise / Martens, John W M / Span, Paul N / Lakhani, Sunil R / Vincent-Salomon, Anne / Sotiriou, Christos / Tutt, Andrew / Thompson, Alastair M / Van Laere, Steven / Richardson, Andrea L / Viari, Alain / Campbell, Peter J / Stratton, Michael R / Nik-Zainal, Serena. ·Wellcome Trust Sanger Institute, Hinxton, UK. · Guy's and St Thomas' NHS Trust, London, UK. · Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. · Oncology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Little Chesterford, UK. · Translational Research Lab Department, Centre Léon Bérard, Lyon, France. · Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics, Erasmus University Medical Center, Rotterdam, the Netherlands. · Centre for Clinical Research and School of Medicine, The University of Queensland, Brisbane, Queensland, Australia. · Memorial Sloan Kettering Cancer Center, New York, New York, USA. · Cancer Research Laboratory, Faculty of Medicine, University of Iceland, Reykjavik, Iceland. · Department of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea. · European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, UK. · Department of Molecular Biology, Faculties of Science and Medicine, Radboud University, Nijmegen, the Netherlands. · Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands. · Department of Cancer Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. · K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. · Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. · Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands. · Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. · Department of Pathology, Institut Curie, Paris, France. · INSERM U934, Institut Curie, Paris, France. · Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium. · Breast Cancer Now Research Unit, King's College, London, UK. · Breast Cancer Now Toby Robin's Research Centre, Institute of Cancer Research, London, UK. · Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. · Translational Cancer Research Unit, Center for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. · HistoGeneX, Wilrijk, Belgium. · Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA. · Dana-Farber Cancer Institute, Boston, Massachusetts, USA. · Equipe Erable, INRIA Grenoble-Rhône-Alpes, Montbonnot-Saint Martin, France. · Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France. · East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. ·Nat Med · Pubmed #28288110.

ABSTRACT: Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic mutations in BRCA1 and/or BRCA2 (BRCA1/BRCA2) also confer selective sensitivity to PARP inhibitors. Thus, assays to detect BRCA1/BRCA2-deficient tumors have been sought. Recently, somatic substitution, insertion/deletion and rearrangement patterns, or 'mutational signatures', were associated with BRCA1/BRCA2 dysfunction. Herein we used a lasso logistic regression model to identify six distinguishing mutational signatures predictive of BRCA1/BRCA2 deficiency. A weighted model called HRDetect was developed to accurately detect BRCA1/BRCA2-deficient samples. HRDetect identifies BRCA1/BRCA2-deficient tumors with 98.7% sensitivity (area under the curve (AUC) = 0.98). Application of this model in a cohort of 560 individuals with breast cancer, of whom 22 were known to carry a germline BRCA1 or BRCA2 mutation, allowed us to identify an additional 22 tumors with somatic loss of BRCA1 or BRCA2 and 47 tumors with functional BRCA1/BRCA2 deficiency where no mutation was detected. We validated HRDetect on independent cohorts of breast, ovarian and pancreatic cancers and demonstrated its efficacy in alternative sequencing strategies. Integrating all of the classes of mutational signatures thus reveals a larger proportion of individuals with breast cancer harboring BRCA1/BRCA2 deficiency (up to 22%) than hitherto appreciated (∼1-5%) who could have selective therapeutic sensitivity to PARP inhibition.